⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Canopy Immuno-Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Canopy Immuno-Therapeutics
↗Megadim, Israel
Canopy Immuno-Therapeutics is an Israeli private biotechnology company developing antigen-specific biologics for antibody-mediated autoimmune disease. Its platform, initially described as Reverse Immunization and now positioned around Antigen-Drug Conjugates (AgDCs), is designed to use disease-defining autoantigens to selectively clear pathogenic autoantibodies and eliminate autoreactive B-cell clones while preserving protective immunity. The company is focused primarily on myasthenia gravis and has also disclosed programs or patent activity relevant to Graves disease, pemphigus, and immune thrombocytopenia. ([canopy-biotech.com](https://canopy-biotech.com/))
The company was legally incorporated in Israel on October 2, 2019, while its website describes the operating company as founded in 2020 by Dr. Kfir Oved. Canopy is privately held, headquartered in Megadim near Haifa, and remains an early-stage clinical-development biotech. Its lead disclosed asset is MGAC-007, with first-in-human Phase 1 testing in myasthenia gravis planned for Q4 2026; no publicly registered clinical trial, FDA approval, or EMA approval was located in the reviewed sources. ([en.checkid.co.il](https://en.checkid.co.il/company/CANOPY%2BIMMUNO-THERAPEUTICS%2B%2BLTD-g3LVOAO-516091204?utm_source=openai))
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:-
Industry:Biotechnology
Sub-Industry:Autoimmune biologics / precision immunology
SIZE & FINANCIALS
Employees:11-50
Founded:2019
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:$21.85M disclosed Series A; earlier seed financing amount undisclosed
Investors:Morningside Venture Investments Limited — led the disclosed $21.85M Series A round. ([linkedin.com](https://www.linkedin.com/posts/arnontadmorlevy_congratulations-to-morningside-venture-investments-activity-7160663486392381442-ErLH?utm_source=openai)), TLV Partners — participated in the December 2019 seed round. ([finder.startupnationcentral.org](https://finder.startupnationcentral.org/company_page/canopy-immuno-therapeutics?utm_source=openai)), Redmile Group — named among Canopy's investor/supporter network in a company update; investment amount and round not publicly specified. ([linkedin.com](https://www.linkedin.com/company/canopy-biotech?utm_source=openai))
PIPELINE
Stage:Preclinical
Lead Drug Stage:Preclinical; first-in-human Phase 1 in myasthenia gravis planned for Q4 2026
Modalities:Antigen-drug conjugates (AgDCs), Ig-like fusion proteins, Recombinant proteins, Autoantigen-targeted biologics, Linker-payload biologics
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:European Innovation Council Accelerator / European Investment Bank — Canopy was selected for EIC Accelerator 2026 blended-finance support under the ADCure project. The public award listing does not disclose the grant/equity amount. ([webgate.ec.europa.eu](https://webgate.ec.europa.eu/circabc-ewpp/d/d/workspace/SpacesStore/8e8173cc-002f-4329-b7ff-2478527722b1/download?utm_source=openai)), ISERD — Israel-Europe R&D Directorate, cited by Canopy as providing guidance and support connected with European clinical development. ([linkedin.com](https://www.linkedin.com/company/canopy-biotech?utm_source=openai)), BIO International Convention — company presentation and partnering exposure in June 2026; BIO materials state that five products are potentially available for licensing. ([convention.bio.org](https://convention.bio.org/2026-sessions-and-courses/canopy-immuno-therapeutics?utm_source=openai))
COMPETITION
Position:Emerging
Competitors:Cabaletta Bio — antigen-specific immune-reset and autoimmune cell-therapy approaches, argenx — FcRn and antibody-mediated autoimmune disease therapies, Alexion, AstraZeneca Rare Disease — complement and neuromuscular autoimmune therapies, UCB — myasthenia gravis and antibody-mediated autoimmune disease therapies, Cartesian Therapeutics — autoimmune cell-therapy approaches, Anokion — antigen-specific immune-tolerance biologics, Selecta Biosciences — immune-tolerance and antigen-specific immune-modulation approaches
LEADERSHIP
Key Executives:
Dr. Kfir Oved - Founder, CEO and Board Member
Dr. Galit Denkberg - Vice President, Discovery
Dr. Sharon Reef - Vice President, CMC
Dr. Roei Mazor - Vice President, Clinical Development and Medical Affairs
Inbar Arman - Director of Immunology / IP Manager
Scientific Founders:Dr. Kfir Oved — founder; molecular immunology and physician-scientist background. ([canopy-biotech.com](https://canopy-biotech.com/team/))
Board Members:Dr. Cedric Francois — Chairman; CEO of Apellis Pharmaceuticals. ([canopy-biotech.com](https://canopy-biotech.com/team/)), John Cox — Board Member; CEO of Dyne Therapeutics. ([canopy-biotech.com](https://canopy-biotech.com/team/)), Dr. Westley Nolin — Board Member; life-sciences team member at Morningside Venture. ([canopy-biotech.com](https://canopy-biotech.com/team/)), Dr. Kfir Oved — Founder, CEO and Board Member. ([canopy-biotech.com](https://canopy-biotech.com/team/)), Shahar Tzafrir — Board Member; Managing Partner at TLV Partners. ([canopy-biotech.com](https://canopy-biotech.com/team/))
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Canopy Immuno-Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.